EUR 187.45
(0.83%)
Year | Net Income | Net Income Growth |
---|---|---|
2023 | 343 Million EUR | -17.94% |
2022 | 418 Million EUR | -60.49% |
2021 | 1.05 Billion EUR | 44.54% |
2020 | 732 Million EUR | -7.58% |
2019 | 792 Million EUR | -1.0% |
2018 | 800 Million EUR | 6.24% |
2017 | 753 Million EUR | 44.81% |
2016 | 520 Million EUR | 96.97% |
2015 | 264 Million EUR | 129.57% |
2014 | 115 Million EUR | 40.24% |
2013 | 82 Million EUR | -67.97% |
2012 | 256 Million EUR | 8.94% |
2011 | 235 Million EUR | 125.96% |
2010 | 104 Million EUR | -79.77% |
2009 | 514 Million EUR | 1095.35% |
2008 | 43 Million EUR | -73.29% |
2007 | 161 Million EUR | -56.13% |
2006 | 367 Million EUR | -51.39% |
2005 | 755 Million EUR | 107.97% |
2004 | 363.04 Million EUR | 6.88% |
2003 | 339.67 Million EUR | 2.37% |
2002 | 331.81 Million EUR | 0.0% |
Year | Net Income | Net Income Growth |
---|---|---|
2024 Q2 | 208 Million EUR | 0.0% |
2023 Q2 | 311 Million EUR | 0.0% |
2023 FY | 343 Million EUR | -17.94% |
2023 Q4 | 32 Million EUR | 0.0% |
2022 FY | 418 Million EUR | -60.49% |
2022 Q2 | 399 Million EUR | 0.0% |
2022 Q4 | 19 Million EUR | 0.0% |
2021 Q2 | 571 Million EUR | 0.0% |
2021 FY | 1.05 Billion EUR | 44.54% |
2021 Q4 | 487 Million EUR | 0.0% |
2020 FY | 732 Million EUR | -7.58% |
2020 Q4 | 369 Million EUR | 0.0% |
2020 Q2 | 363 Million EUR | 0.0% |
2019 Q4 | 381 Million EUR | 0.0% |
2019 FY | 792 Million EUR | -1.0% |
2019 Q2 | 411 Million EUR | 0.0% |
2018 Q2 | 550 Million EUR | 0.0% |
2018 FY | 800 Million EUR | 6.24% |
2017 Q4 | 322 Million EUR | 0.0% |
2017 FY | 753 Million EUR | 44.81% |
2017 Q2 | 430 Million EUR | 0.0% |
2016 FY | 520 Million EUR | 96.97% |
2016 Q2 | 309 Million EUR | 0.0% |
2015 FY | 264 Million EUR | 129.57% |
2015 Q4 | 25 Million EUR | 0.0% |
2015 Q2 | 239 Million EUR | 0.0% |
2014 Q4 | 29 Million EUR | 0.0% |
2014 FY | 115 Million EUR | 40.24% |
2014 Q2 | 86 Million EUR | 0.0% |
2013 Q4 | 26 Million EUR | 0.0% |
2013 Q2 | 56 Million EUR | 0.0% |
2013 FY | 82 Million EUR | -67.97% |
2012 Q3 | 58.75 Million EUR | 0.0% |
2012 FY | 256 Million EUR | 8.94% |
2012 Q4 | 48.75 Million EUR | -17.02% |
2012 Q2 | 58.75 Million EUR | 0.0% |
2012 Q1 | 58.75 Million EUR | 0.0% |
2011 Q1 | 55.25 Million EUR | 0.0% |
2011 Q2 | 55.25 Million EUR | 0.0% |
2011 Q3 | 55.25 Million EUR | 0.0% |
2011 Q4 | 58.75 Million EUR | 6.33% |
2011 FY | 235 Million EUR | 125.96% |
2010 Q4 | 55.25 Million EUR | 110.48% |
2010 Q2 | 26.25 Million EUR | 0.0% |
2010 Q3 | 26.25 Million EUR | 0.0% |
2010 Q1 | 26.25 Million EUR | 0.0% |
2010 FY | 104 Million EUR | -79.77% |
2009 Q4 | 26.25 Million EUR | -79.29% |
2009 FY | 514 Million EUR | 1095.35% |
2009 Q2 | 126.75 Million EUR | 0.0% |
2009 Q3 | 126.75 Million EUR | 0.0% |
2009 Q1 | 126.75 Million EUR | 0.0% |
2008 Q3 | -3.25 Million EUR | 0.0% |
2008 FY | 43 Million EUR | -73.29% |
2008 Q1 | -3.25 Million EUR | 0.0% |
2008 Q2 | -3.25 Million EUR | 0.0% |
2008 Q4 | 126.75 Million EUR | 4000.0% |
2007 Q4 | -3.25 Million EUR | -108.18% |
2007 FY | 161 Million EUR | -56.13% |
2007 Q3 | 39.75 Million EUR | 0.0% |
2007 Q2 | 39.75 Million EUR | 0.0% |
2007 Q1 | 39.75 Million EUR | 0.0% |
2006 Q3 | 91.75 Million EUR | 0.0% |
2006 Q4 | 39.75 Million EUR | -56.68% |
2006 Q2 | 91.75 Million EUR | 0.0% |
2006 FY | 367 Million EUR | -51.39% |
2006 Q1 | 91.75 Million EUR | 0.0% |
2005 Q4 | 91.75 Million EUR | 35.93% |
2005 FY | 755 Million EUR | 107.97% |
2005 Q2 | 67.5 Million EUR | 0.0% |
2005 Q3 | 67.5 Million EUR | 0.0% |
2005 Q1 | 67.5 Million EUR | 0.0% |
2004 Q2 | 90.72 Million EUR | 0.0% |
2004 FY | 363.04 Million EUR | 6.88% |
2004 Q1 | 90.72 Million EUR | 0.0% |
2004 Q3 | 90.72 Million EUR | 0.0% |
2004 Q4 | 67.5 Million EUR | -25.6% |
2003 Q4 | 90.72 Million EUR | 7.04% |
2003 Q3 | 84.75 Million EUR | 0.0% |
2003 Q1 | 84.75 Million EUR | 0.0% |
2003 Q2 | 84.75 Million EUR | 0.0% |
2003 FY | 339.67 Million EUR | 2.37% |
2002 Q3 | 82.51 Million EUR | 0.0% |
2002 Q2 | 82.51 Million EUR | 0.0% |
2002 Q1 | 82.51 Million EUR | 0.0% |
2002 FY | 331.81 Million EUR | 0.0% |
2002 Q4 | 84.75 Million EUR | 2.71% |
2001 Q4 | 82.51 Million EUR | 0.0% |
Name | Net Income | Net Income Difference |
---|---|---|
ABIONYX Pharma SA | -3.51 Million EUR | 9849.858% |
ABIVAX Société Anonyme | -147.74 Million EUR | 332.165% |
Adocia SA | -21.16 Million EUR | 1720.83% |
Aelis Farma SA | -5.07 Million EUR | 6854.628% |
Biophytis S.A. | -17.02 Million EUR | 2114.566% |
Advicenne S.A. | -7.03 Million EUR | 4978.396% |
genOway Société anonyme | 1.56 Million EUR | -21780.931% |
IntegraGen SA | -171.39 Thousand EUR | 200217.854% |
Medesis Pharma S.A. | -3.95 Million EUR | 8762.73% |
Neovacs S.A. | -8.74 Million EUR | 4022.937% |
NFL Biosciences SA | -3.74 Million EUR | 9257.715% |
Plant Advanced Technologies SA | 79.16 Thousand EUR | -433150.388% |
Quantum Genomics Société Anonyme | -3.17 Million EUR | 10916.958% |
Sensorion SA | -22.06 Million EUR | 1654.611% |
Theranexus Société Anonyme | -6.82 Million EUR | 5123.468% |
TME Pharma N.V. | -6.73 Million EUR | 5192.043% |
Valbiotis SA | -7.36 Million EUR | 4755.266% |
TheraVet SA | -1.57 Million EUR | 21937.3% |
Valerio Therapeutics Société anonyme | -20.34 Million EUR | 1786.001% |
argenx SE | -272.91 Million EUR | 225.68% |
BioSenic S.A. | -28.77 Million EUR | 1291.883% |
Celyad Oncology SA | -8.44 Million EUR | 4160.133% |
DBV Technologies S.A. | -67.26 Million EUR | 609.89% |
Galapagos NV | 211.69 Million EUR | -62.024% |
Genfit S.A. | -28.89 Million EUR | 1287.098% |
GeNeuro SA | -14.75 Million EUR | 2424.321% |
Hyloris Pharmaceuticals SA | -15.38 Million EUR | 2330.169% |
Innate Pharma S.A. | -7.57 Million EUR | 4631.044% |
Inventiva S.A. | -110.42 Million EUR | 410.615% |
MaaT Pharma SA | -19.71 Million EUR | 1839.616% |
MedinCell S.A. | -25.03 Million EUR | 1469.918% |
Nanobiotix S.A. | -39.7 Million EUR | 963.98% |
Onward Medical N.V. | -36.18 Million EUR | 1048.011% |
Oryzon Genomics S.A. | -3.35 Million EUR | 10329.819% |
OSE Immunotherapeutics SA | -23 Million EUR | 1591.11% |
Oxurion NV | -18.96 Million EUR | 1908.213% |
Pharming Group N.V. | -9.75 Million EUR | 3615.573% |
Poxel S.A. | -35.09 Million EUR | 1077.486% |
GenSight Biologics S.A. | -26.22 Million EUR | 1408.162% |
Transgene SA | -22.32 Million EUR | 1636.188% |
Financière de Tubize SA | 88.15 Million EUR | -289.104% |
Valneva SE | -101.42 Million EUR | 438.168% |
Vivoryon Therapeutics N.V. | -28.34 Million EUR | 1310.218% |